CD33 and acute myeloid leukemia: In studies using CD64- MOLM-13 or CD64+ THP-1 AML cell lines as target cells, CC-96191 led to greater antibody-dependent cellular cytotoxicity (ADCC) than the parental CD33 mAb I07, the CD33 mAb lintuzumab, or an afucosylated version of CD33 mAb I07 (Supplemental Figure S1).